PROCEPT BioRobotics Corporation (PRCT)

From the record

PROCEPT BioRobotics Corporation's filings since 2017 show no warning events in the scan: no bankruptcy or receivership notice, no debt default notice, no exchange listing notice, no restatement warning, no auditor change, no material cyber incident and no late-report notice (its current reports).

From the record

PROCEPT BioRobotics Corporation's 6 filed years say what it did: revenue went from $8 million in fiscal 2020 to $308 million in fiscal 2025, up 109.1% a year; it rose in 5 of 5 years; it never fell from a peak; net income was positive in 0 of 6 of those years (its annual reports).

From the record

Return on equity: in the fiscal year ended 2025-12-31, PROCEPT BioRobotics Corporation lost about 26 cents for every dollar of shareholders' money, and gross profitability: its products earned about 39 cents per dollar of everything the company owns. Leverage: it owed about 28 cents per dollar of assets, and net share issuance: its share count grew 6.6% over the year (the filed statements).

From the record

PROCEPT BioRobotics Corporation's standing among 109 graded names in its industry family: revenue of $308 million in fiscal 2025 ranks in the top 33% by size; a net margin of -31% ranks in the bottom 43%; revenue growth of 60.1% a year over the last 3 filed years ranks in the top 11% (its annual reports).

From the record

PROCEPT BioRobotics Corporation's leadership, from its insiders' filings and its current reports: the chief executive on the record is Wood, Larry L (President, CEO, as filed), filing under that title since 2025-09-04, 1.2 years (bottom 26% of its family); the 14 officers and directors filing in the last fifteen months have been on the record a median of 5 years (bottom 41%); 6 officer or director changes were reported on Form 8-K since 2023-11-13, against the 14 people in charge now (top 39%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

PROCEPT BioRobotics Corporation's room to grow, from the newest filed statements (fiscal 2025): cash of $290 million against debt of $52 million leaves 46.8% of its assets as net cash, top 17% of its family; cash from operations less capital spending is -18.9% of revenue (bottom 41%); a gross margin of 63.7% (top 43%); research spending of 23.1% of revenue (top 35%) (its annual report).

From the record

PROCEPT BioRobotics Corporation's growth drivers, from the filed years to fiscal 2025: revenue grew 60.1% a year over the last three filed years against 109.1% over all 6, slowing (bottom 4% of its family); the newest year grew 37.2% (top 17%); research spending grew 35% a year (top 10%); capital spending grew 52.2% a year (top 9%) (its annual reports). PROCEPT BioRobotics Corporation tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.

From the record

PROCEPT BioRobotics Corporation's newest year against its own record: revenue of $308 million in fiscal 2025 came in 20.7% below the $388 million its prior three years' pace pointed to (bottom 20% of its family); net income of $96 million against a prior three-year average of $95 million (bottom 37%); a net margin of -31% against -78.2% before (top 18%) (its annual reports).